Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors (Q58614417)
Jump to navigation
Jump to search
scientific article published on 28 February 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors |
scientific article published on 28 February 2014 |
Statements
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors (English)
Kyriakos P Papadopoulos
Ben Markman
Amita Patnaik
Anthony W Tolcher
José Baselga
Weiliang Shi
Coumaran Egile
Rodrigo Ruiz-Soto
A Douglas Laird
Dale Miles
Patricia M Lorusso
28 February 2014